.jpg)
Synopsis: Caplin Point Laboratories' shares dipped 1.40% despite a successful US FDA inspection at their Gummidipoondi facility, reflecting strong regulatory compliance and steady market performance.
Caplin Point Laboratories' shares fell by 1.40% on Friday despite a positive outcome from a recent unannounced US FDA inspection at their Gummidipoondi facility. The inspection, which occurred between August 5 and August 9, 2024, concluded with zero observations, reaffirming the company's commitment to regulatory compliance.
The stock closed at Rs 1501.90, down from the previous close of Rs 1481.15 on the BSE, with a market capitalization of Rs 18,112 crore. Despite the recent dip, the stock has shown a 49% increase over the past year and delivered a 10.87% return in 2024.
Caplin Point Laboratories continues to focus on producing and marketing a wide range of generic and branded pharmaceutical products, primarily for overseas markets.
Disclaimer: Investors should conduct their own research and consult with financial advisors before making investment decisions.
